- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp stock price live, this page displays NASDAQ ADPT stock exchange data. View the ADPT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adaptive Biotechnologies Corp real time stock price chart below.
What Is the Adaptive Biotechnologies Corp Stock Price Today?
The Adaptive Biotechnologies Corp stock price today is 28.350.
What Is the Stock Symbol for Adaptive Biotechnologies Corp?
The stock symbol for Adaptive Biotechnologies Corp is "ADPT."
What Stock Exchange Does Adaptive Biotechnologies Corp Trade On?
Adaptive Biotechnologies Corp is listed and trades on the NASDAQ stock exchange.
Is Adaptive Biotechnologies Corp a Good Stock to Buy?
Determining whether Adaptive Biotechnologies Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADPT quote. (ISIN: US00650F1093)
What Is the Adaptive Biotechnologies Corp Stock Price Today?
The Adaptive Biotechnologies Corp stock price today is 28.350.
What Is the Stock Symbol for Adaptive Biotechnologies Corp?
The stock symbol for Adaptive Biotechnologies Corp is "ADPT."
What Stock Exchange Does Adaptive Biotechnologies Corp Trade On?
Adaptive Biotechnologies Corp is listed and trades on the NASDAQ stock exchange.
Is Adaptive Biotechnologies Corp a Good Stock to Buy?
Determining whether Adaptive Biotechnologies Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADPT quote. (ISIN: US00650F1093)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.310
28.410
52 wk Range
12.000
29.960
ADPT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.31028.410
52 wk Range
12.00029.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADPT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
28.313
Downside
-0.13%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 28.313
(-0.13% Downside)
Adaptive Biotechnologies Corp Earnings Call Summary for Q1/2026
- Q1 2026 revenue hit $70.9M, beating forecasts by 16.4% with MRD segment up 53% YoY to $67.1M, driving 45% total revenue growth.
- Company raised full-year 2026 MRD revenue guidance to $260M-$270M from $255M-$265M, expecting 35%+ clinical volume growth.
- Sequencing gross margin expanded to 70% from 62% YoY; cash position remains strong at $222M despite $20M net loss for the quarter.
- Stock rose 1.38% after-hours on earnings beat; operating expenses increased 10% YoY to $90.1M, pressuring near-term profitability.
- Immune Medicine segment posted $10.4M loss; CEO cited 'accelerating momentum' in MRD business with disciplined execution driving margin expansion.
Last Updated: 2026-05-05, 05:24 p/m
Read Full TranscriptEarnings
Latest Release
Jul 29, 2026
EPS / Forecast
-0.25 / -0.14
Revenue / Forecast
71.55M / 65.75M
Compare ADPT to Peers and Sector
Metrics to compare | ADPT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADPTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −70.9x | −15.1x | −0.3x | |
PEG Ratio | −1.38 | −0.10 | 0.00 | |
Price/Book | 31.7x | 6.9x | 2.6x | |
Price / LTM Sales | 14.7x | 9.8x | 3.0x | |
Upside (Analyst Target) | 3.4% | 3.4% | 58.6% | |
Fair Value Upside | Unlock | −28.7% | 8.4% | Unlock |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Adaptive Biotechnologies (ADPT) Stock Price Today?
The Adaptive Biotechnologies stock price today is 28.350 USD.
What Stock Exchange Does Adaptive Biotechnologies Trade On?
Adaptive Biotechnologies is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Adaptive Biotechnologies?
The stock symbol for Adaptive Biotechnologies is "ADPT."
What Is the Adaptive Biotechnologies Market Cap?
As of today, Adaptive Biotechnologies market cap is 4.370B USD.
What Is Adaptive Biotechnologies's Earnings Per Share (TTM)?
The Adaptive Biotechnologies EPS (TTM) is -0.411.
When Is the Next Adaptive Biotechnologies Earnings Date?
Adaptive Biotechnologies will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is ADPT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Adaptive Biotechnologies Stock Split?
Adaptive Biotechnologies has split 0 times.
How Many Employees Does Adaptive Biotechnologies Have?
Adaptive Biotechnologies has 624 employees.
What is the current trading status of Adaptive Biotechnologies (ADPT)?
As of Oct 03, 2026, Adaptive Biotechnologies (ADPT) is trading at a price of 28.350 USD, with a previous close of 28.350 USD. The stock has fluctuated within a day range of 27.310 USD to 28.410 USD, while its 52-week range spans from 12.000 USD to 29.960 USD.
What Is Adaptive Biotechnologies (ADPT) Price Target According to Analysts?
The average 12-month price target for Adaptive Biotechnologies is 28.313 USD, with a high estimate of 35 USD and a low estimate of 21 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -0.13% Downside potential.
What Is the ADPT Premarket Price?
ADPT's last pre-market stock price is 27.500 USD. The pre-market share volume is 5,200.000, and the stock has decreased by 0.130, or 0.470%.
What Is the ADPT After Hours Price?
ADPT's last after hours stock price is 27.000 USD, the stock has decreased by -1.350, or -4.760%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.